These changes are secondary to weight loss and improved glycemic control rather than direct lipid-lowering effects
Research from the STEP trials shows that nausea affects 40% to 44% of participants, while constipation, diarrhea, and vomiting are also common
By activating GIP receptors alongside GLP-1 receptors simultaneously, tirzepatide creates synergistic metabolic effects that exceed what either hormone achieves alone
Compounding and the FDA: Questions and answers
If you used bovine (beef/cow) insulin anytime after 1980, you aren't allowed to donate
During Ozempic clinical trials, 20% of participants experienced nausea, and 10% noted occurrences of vomiting, which are both symptoms prevalent in cases of gastroparesis